List of Contents

In-vitro Diagnostics Enzymes Market Size, Share, and Trends 2024 to 2033

In-vitro Diagnostics Enzymes Market (By Enzyme Type: Proteases, Polymerase & Transcriptase, Ribonuclease, Others; By Disease Type: Infectious Disease, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, Others; By Technology Type: Histology Assays, Molecular Diagnostics, Clinical Chemistry; By End-use: Pharma & Biotech, Hospital & Diagnostic Labs, Contract Research Organizations, Academic Labs) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : April 2024
  • Report Code : 4095
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on In-vitro Diagnostics Enzymes Market 

5.1. COVID-19 Landscape: In-vitro Diagnostics Enzymes Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global In-vitro Diagnostics Enzymes Market, By Enzyme Type

8.1. In-vitro Diagnostics Enzymes Market, by Enzyme Type, 2024-2033

8.1.1. Proteases

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Polymerase & Transcriptase

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Ribonuclease

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global In-vitro Diagnostics Enzymes Market, By Disease Type

9.1. In-vitro Diagnostics Enzymes Market, by Disease Type, 2024-2033

9.1.1. Infectious Disease

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Diabetes

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Oncology

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Cardiology

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Nephrology

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. Autoimmune diseases

9.1.6.1. Market Revenue and Forecast (2021-2033)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global In-vitro Diagnostics Enzymes Market, By Technology Type 

10.1. In-vitro Diagnostics Enzymes Market, by Technology Type, 2024-2033

10.1.1. Histology Assays

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Molecular Diagnostics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Clinical Chemistry

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global In-vitro Diagnostics Enzymes Market, By End-use 

11.1. In-vitro Diagnostics Enzymes Market, by End-use, 2024-2033

11.1.1. Pharma & Biotech

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Hospital & Diagnostic Labs

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Contract Research Organizations (CROs)

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Academic Labs

11.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global In-vitro Diagnostics Enzymes Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.1.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.1.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.1.4. Market Revenue and Forecast, by End-use (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.1.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.1.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.2.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.2.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.7.4. Market Revenue and Forecast, by End-use (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.2.8.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.3.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.3.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.7.4. Market Revenue and Forecast, by End-use (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.3.8.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.4.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.6.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.7.4. Market Revenue and Forecast, by End-use (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.4.8.4. Market Revenue and Forecast, by End-use (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.5.5.4. Market Revenue and Forecast, by End-use (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Enzyme Type (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Technology Type (2021-2033)

12.5.6.4. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 13. Company Profiles

13.1. Biocatalysts Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Amicogen

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Dyadic International

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. BBI Solutions

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Affymetrix

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. American Laboratories

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck KGaA

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Codexis, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. F. Hoffmann-La Roche Ltd.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Amano Enzyme Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us